$0.10
(Market cap
$9,272 Mln
Revenue (TTM)
$2,100 Mln
P/E Ratio
22.7
P/B Ratio
2.7
Div. Yield
0.8 %
Quality Score
/10
Growth Score
/10
Valuation Score
/10
Momentum Score
/10
Stock Range
Today’s Range
52 Week Range
Liquidity
Fundamentals
-
Net Profit (TTM)
$0 Mln
-
ROE
0.1 %
-
ROCE
-- %
-
Industry P/E
--
-
EV/EBITDA
14.3
-
Debt to Equity
0.5
-
Book Value
$--
-
EPS
$1.9
-
Face value
--
-
Shares outstanding
206,495,000
10 Years Aggregate
CFO
$4,230.17 Mln
EBITDA
$5,475.50 Mln
Net Profit
$1,864.21 Mln
Performance
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
Qiagen N.V. - ADR
| -8.3 | 4.8 | 18.6 | -11.4 | -5.1 | -7.0 | 3.5 |
|
BSE Sensex
| -9.1 | -1.5 | 2.9 | -3.6 | 5.9 | 6.0 | 10.5 |
|
S&P Small-Cap 600#
| -5.8 | -5.3 | -13.7 | -6.3 | 5.3 | 3.0 | 5.5 |
|
Company
|
2025
|
2023
|
2022
|
2021
|
2020
|
2019
|
|---|---|---|---|---|---|---|
|
Qiagen N.V. - ADR
| -1.8 | -12.9 | -10.3 | 5.2 | 56.4 | -1.9 |
|
S&P Small-Cap 600
| 4.0 | 13.9 | -17.4 | 25.3 | 9.6 | 20.9 |
|
BSE Sensex
| 9.1 | 18.7 | 4.4 | 22.0 | 15.8 | 14.4 |
Essential Checks
View DetailsIs there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
Financials
View DetailsKey Ratios
View Details
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Peers
View DetailsCompany |
Price ($) | Market Cap ($ Mln) | Revenue (TTM) | Net Profit (TTM) | OPM (%) | ROE (%) | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
|
Qiagen N.V. - ADR
|
43.4 | 9,271.6 | 2,100.4 | 409.3 | 23.8 | 11.5 | 22.7 | 2.7 |
| 7.3 | 2,703.6 | 4.5 | -668.2 | -15,198.8 | -335.5 | -- | 15.5 | |
| 2.2 | 328.6 | 0.0 | -39.1 | 281,529.0 | -41.7 | -- | 2.0 | |
| 34.9 | 2,479.6 | 0.0 | -171.6 | -- | -60 | -- | 7.4 | |
| 2.1 | 323.2 | 18.5 | -42.3 | -230.0 | -65.7 | -- | 3.5 | |
| 47.9 | 3,379.5 | 18.7 | -252.2 | -1,047.2 | -96.5 | -- | 10.6 |
Shareholding Pattern
View DetailsAbout Qiagen N.V. - ADR
Qiagen N.V. provides sample to insight solutions that transform biological samples into molecular insights worldwide. The company offers sample technology consumables, such as nucleic acid stabilization and purification kits for sample materials,... manual and automated processing for genotyping, gene expression, and viral and bacterial analysis, as well as silica membranes and magnetic bead technologies; secondary sample technology consumables, including kits and components for purification of nucleic acids; and instruments for nucleic acid purification, quality control, and accessories. It also provides Immune response consumables, such as interferon-gamma release assay for TB testing, and assays for post-transplant testing and viral load monitoring; oncology and sexual and reproductive health consumables, inclsuing assays for prenatal testing and detection of sexually transmitted diseases and HPV; assays for analysis of genomic variants; and sample to insight instruments, including one-step molecular analysis of hard-to-diagnose syndromes, and integrated PCR testing. The company offers research PCR consumables, such as quantitative PCR, reverse transcription, and combinations kits for analysis of gene expression, genotyping and gene regulation, and running on QIAGEN instruments and technologies; human ID/forensics assay consumables comprising short tandem repeat assays for human ID, and assays for food contamination; PCR instruments, including digital PCR and qPCR solutions; and developed and configured enzymes and PCR solutions. It offers NGS gene panels, library prep kits and components, and whole genome amplification; DNA methylation analysis; QIAGEN consumables and instruments; bioinformatics solutions; and sequence-based assays forensic genetic genealog services. it provides software-as-a-service. It serves molecular diagnostics and life sciences sectors. The company was founded in 1984 and is headquartered in Venlo, the Netherlands. Read more
-
CEO, MD & Member of Management Board
Mr. Thierry Bernard
-
CEO, MD & Member of Management Board
Mr. Thierry Bernard
-
Headquarters
Venlo
-
Website
Value Research Ratings
Our rating system has guided millions of investors in the past 20 years.
FAQs for Qiagen N.V. - ADR
What is the current share price of Qiagen NV - ADR Today?
The share price of Qiagen NV - ADR is $43.39 (NYSE) as of 01-Sep-2026 16:00 EDT. Qiagen NV - ADR has given a return of -5.1% in the last 3 years.
What is the current PB & PE ratio of Qiagen NV - ADR?
The P/E ratio of Qiagen NV - ADR is 22.68 times as on 21-Aug-2026.
The P/B ratio of Qiagen NV - ADR is 2.74 times as on 21-Aug-2026, a 63 discount to its peers’ median range of 7.40 times.
PE & PB ratio at the end of financial year.
| Year | P/E Ratio | P/B Ratio |
|---|---|---|
2025 |
21.99 |
2.47 |
2024 |
116.14 |
2.72 |
2023 |
28.48 |
2.55 |
2022 |
26.33 |
3.21 |
2021 |
25.13 |
4.16 |
What is the 52 Week High and Low of Qiagen NV - ADR?
The 52-week high and low of Qiagen NV - ADR are Rs 56.19 and Rs 32.53 as of 02-Sep-2026.
What is the market cap of Qiagen NV - ADR?
Qiagen NV - ADR has a market capitalisation of $ 9,272 Mln as on 21-Aug-2026. As per SEBI classification, it is a Small Cap company.
Should I invest in Qiagen NV - ADR?
Before investing in Qiagen NV - ADR, assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.